ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO532

Subclinical Primary Aldosteronism and eGFR Decline

Session Information

Category: Hypertension and CVD

  • 1602 Hypertension and CVD: Clinical


  • Hundemer, Gregory L., Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
  • Agharazii, Mohsen, Universite Laval, Quebec, Quebec, Canada
  • Madore, Francois, Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada
  • Goupil, Remi, Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada

Primary aldosteronism (PA), characterized by renin-independent aldosterone secretion, is the most common and modifiable form of secondary hypertension. Overt PA predisposes to disproportionately high rates of cardiovascular and kidney disease, independent of blood pressure (BP). Growing evidence suggests that milder forms of renin-independent aldosteronism (ie, Subclinical PA) are highly prevalent yet their clinical significance remains uncertain.


Prospective study of 536 participants aged 40-69 yr and on no BP medications from the randomly sampled, population-based CARTaGENE cohort (Canada). Using aldosterone and renin levels from enrollment, we employed multivariable linear regression models to measure the association between the aldosterone-renin ratio (ARR) and eGFR (via the 2021 CKD-EPICr/CysC equation) measured at enrollment and after 5-7 years of follow-up.


The mean (SD) age, eGFR, and systolic BP were 55 (7) years, 107 (13) mL/min/1.73m2, and 132 (11) mmHg, respectively. Higher ARR was successively associated with steeper annual eGFR decline with ARR Tertile 3 having a 74% steeper decline than ARR Tertile 1 (1.18 vs. 0.68 mL/min/1.73m2/yr, P=0.01; Fig. 1). On multivariable linear regression, higher ARR was associated with steeper annual eGFR decline (P=0.03; Fig. 2).


In a randomly sampled, population-based cohort of individuals on no antihypertensive medication, Subclinical PA was associated with steeper eGFR decline, independent of BP. Subclinical PA may serve as a potentially modifiable risk factor to prevent or slow CKD.